Skip to content

Study · Observational study · n = 123 · 2025

11 results

Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study.

Pardo Lozano F, Rubio Marcos A, Casañ Fernández R, Bartual Rodrigo A, Martínez-Hervás S, Ampudia-Blasco FJ

Endocrinologia, diabetes y nutricion30 May 2025

PMID40450456 (opens in a new tab)DOI10.1016/j.endien.2025.501574 (opens in a new tab)PepBankPUB-40450456
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, prior dulaglutide treatment was linked to a 0.38% HbA1c reduction versus baseline.

    In plain wordsIn patients with diabetes, dulaglutide was linked to lower HbA1c than baseline before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c during prior dulaglutide
    Study

    n = 123

    Comparator
    Baseline before dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16.9 ± 13.8 monthsAs given in this study (human).

    Measurements

    HbA1c reduction
    0.38%
    prior dulaglutide versus baseline

    Source sentences

    Summary
    Previous treatment with dulaglutide (duration 16.9 ± 13.8 mo) reduced HbA1c by 0.38% (p = 0.003 vs. baseline) and weight by -1.3 kg (p = 0.003 vs. baseline).
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, prior dulaglutide treatment was linked to a weight change of -1.3 kg versus baseline.

    In plain wordsIn patients with diabetes, dulaglutide was linked to lower weight than baseline before treatment.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight during prior dulaglutide
    Study

    n = 123

    Comparator
    Baseline before dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 16.9 ± 13.8 monthsAs given in this study (human).

    Measurements

    Weight change
    −1.3 kg
    prior dulaglutide versus baseline

    Source sentences

    Summary
    Previous treatment with dulaglutide (duration 16.9 ± 13.8 mo) reduced HbA1c by 0.38% (p = 0.003 vs. baseline) and weight by -1.3 kg (p = 0.003 vs. baseline).
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  3. 03HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional HbA1c change of -0.43% at 6 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower HbA1c at 6 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c after switch at 6 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.43%
    6 months after switch

    Source sentences

    Summary
    After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (-0.43%, p = 0.000; -0.54%, p = 0.000; -0.38%, p = 0.021; -0.12%, p = 0.622, respectively) and in weight
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  4. 04HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional HbA1c change of -0.54% at 12 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower HbA1c at 12 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c after switch at 12 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.54%
    12 months after switch

    Source sentences

    Summary
    After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (-0.43%, p = 0.000; -0.54%, p = 0.000; -0.38%, p = 0.021; -0.12%, p = 0.622, respectively) and in weight
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  5. 05HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional HbA1c change of -0.38% at 18 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower HbA1c at 18 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c after switch at 18 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.38%
    18 months after switch

    Source sentences

    Summary
    After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (-0.43%, p = 0.000; -0.54%, p = 0.000; -0.38%, p = 0.021; -0.12%, p = 0.622, respectively) and in weight
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  6. 06HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, HbA1c change after switching to semaglutide was -0.12% at 24 months, without statistical significance.

    In plain wordsIn patients with diabetes, HbA1c did not change significantly at 24 months compared with the switch from dulaglutide to semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeHbA1c after switch at 24 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    HbA1c change
    −0.12%
    24 months after switch

    Source sentences

    Summary
    After switching to semaglutide, an additional reduction in HbA1C levels was observed at 6, 12, 18, and 24 mo (-0.43%, p = 0.000; -0.54%, p = 0.000; -0.38%, p = 0.021; -0.12%, p = 0.622, respectively) and in weight
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  7. 07HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional weight change of -2.7 kg at 6 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower weight at 6 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight after switch at 6 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Weight change
    −2.7 kg
    6 months after switch

    Source sentences

    Summary
    and in weight at 6, 12, 18, and 24 mo (-2.7 kg, p = 0.000; -3.7 kg, p = 0.000; -5.4 kg, p = 0.001; -4.2 kg, p = 0.000, respectively) With
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  8. 08HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional weight change of -3.7 kg at 12 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower weight at 12 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight after switch at 12 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Weight change
    −3.7 kg
    12 months after switch

    Source sentences

    Summary
    and in weight at 6, 12, 18, and 24 mo (-2.7 kg, p = 0.000; -3.7 kg, p = 0.000; -5.4 kg, p = 0.001; -4.2 kg, p = 0.000, respectively) With
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  9. 09HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional weight change of -5.4 kg at 18 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower weight at 18 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight after switch at 18 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    Weight change
    −5.4 kg
    18 months after switch

    Source sentences

    Summary
    and in weight at 6, 12, 18, and 24 mo (-2.7 kg, p = 0.000; -3.7 kg, p = 0.000; -5.4 kg, p = 0.001; -4.2 kg, p = 0.000, respectively) With
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  10. 10HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, switching from dulaglutide to semaglutide was linked to an additional weight change of -4.2 kg at 24 months.

    In plain wordsIn patients with diabetes, switching to semaglutide was linked to lower weight at 24 months than at the dulaglutide switch.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight after switch at 24 months
    Study

    n: not reported in source

    Comparator
    At switch from dulaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    Weight change
    −4.2 kg
    24 months after switch

    Source sentences

    Summary
    and in weight at 6, 12, 18, and 24 mo (-2.7 kg, p = 0.000; -3.7 kg, p = 0.000; -5.4 kg, p = 0.001; -4.2 kg, p = 0.000, respectively) With
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.
  11. 11HumanObservational studySafety outcome

    In patients with type 2 diabetes, adverse effect frequency did not differ significantly after switching from dulaglutide to semaglutide.

    In plain wordsIn patients with diabetes, adverse effects did not differ significantly after switching from dulaglutide to semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse effect frequency after switch
    Study

    n: not reported in source

    Comparator
    Prior dulaglutide treatment
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    With no significant differences in the frequency of adverse effects after switching to semaglutide.
    1 context sentence
    Summary · context
    A total of 123 individuals with T2DM on SC dulaglutide, either as monotherapy or with other antihyperglycemic drugs, who switched to SC semaglutide were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.